The United Mitochondrial Disease Foundation Announces Inaugural Venture Philanthropy Investment; The Mito Fund Invests $500k in Pierrepont Therapeutics, Inc.
Entrada Therapeutics, Inc. (NASDAQ:TRDA) Analysts Just Slashed This Year's Estimates [Yahoo! Finance]
Entrada Therapeutics, Inc. (NASDAQ: TRDA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $20.00 price target on the stock.
Entrada Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
Entrada Therapeutics to Present at Upcoming Investor Conferences [Yahoo! Finance]